Tivozanib response prediction

Abstract

A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.

1 . A method of identifying a tumor resistant to treatment with tivozanib, comprising:
 (a) measuring macrophage content by measuring CD68 polypeptide expression in a tissue sample from a tumor obtained from a human patient being considered for treatment with tivozanib, thereby determining a macrophage score; and   (b) comparing the macrophage score measured in step (a) against a threshold score determined by measuring CD68 polypeptide expression in tissue samples of tumors obtained from human patients previously treated with tivozanib and shown to be resistant to tivozanib and human patients previously treated with tivozanib and shown to be sensitive to tivozanib,   wherein a macrophage score above the threshold score indicates that the tumor is resistant to treatment with tivozanib.   
     
     
         2 . The method of  claim 1 , wherein the step of measuring CD68 polypeptide expression is performed by immunohistochemistry. 
     
     
         3 . The method of  claim 1 , wherein the threshold score determination comprises a receiver operator characteristic curve analysis. 
     
     
         4 . The method of  claim 1 , wherein the tumor is selected from the group consisting of a breast tumor, a lung tumor, a kidney tumor, a colorectal tumor, and a pancreatic tumor.